Stevenage Bioscience Catalyst (SBC) offers state-of-the-art facilities that are pre-fitted and ready-for-science. In keeping with the project’s open innovation ethos, the lay-out of the campus is designed to encourage cooperation, dialogue and interaction between tenant companies and also with scientists on the GlaxoSmithKline R&D site.
An initial introduction was made by the NanoKTN at the NanoKTN’s NanoMed mission in 2011 on behalf of Pharmidex to Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst. Following this introduction, Pharmidex secured facilities in the Catalyst’s Bio-Incubator Building for 2013.
Mo Alavijeh, CEO at Pharmidex comments, “We attended the NanoKTN’s NanoMed mission in 2011 and discussed with NanoKTN staff our specialist requirement of bioscience laboratories for the company. Having successfully grown the company, we found ourselves running out of lab space at our old premises. The NanoKTN recommended the SBC and set up a meeting which resulted in Pharmidex moving into their new facilities at SBC. The new laboratory at SBC is perfect for our needs. Not only does it offer state-of-the-art facilities, but also an exciting environment surrounded by similar innovative companies for potential collaboration.”
Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst, said “We’re delighted to welcome Pharmidex to the biosciences hub at Stevenage Bioscience Catalyst. They are a very welcome addition to our vibrant bioscience community. Stevenage Bioscience Catalyst campus has been designed to foster collaboration and interaction between tenant companies with the hope that the combination of opportunity and cooperation will breed innovation and commercial success. We hope that Pharmidex’s new laboratories will deliver further success for the company.”
Pharmidex is unique in providing bespoke integrated assessments of ADMET-PK/PD profiles of drug candidates for major pharma, biotechs, academics and medical charities worldwide, thus speeding up their identification of compounds with the best chance of becoming new medicines. Founded in the UK in 2002, Pharmidex solutions draw on the company’s world-leading expertise in the area of CNS and oncology medicines research and its openness to collaborating with compatible organisations.